An intensive intervention reduced cardiovascular and microvascular events in type 2 diabetes and microalbuminuria
- diabetes defense? Weede, Tom // Natural Health;Sep2007, Vol. 37 Issue 8, p102
The article focuses on how chromium may help manage type 2 diabetes. Research on animals indicates that chromium might make insulin receptors more efficient, so type 2 diabetics need less insulin to metabolize glucose. Chromium comes as a single-ingredient supplement, in combination formulas,...
- Combination Therapy for Type 2 Diabetes. Bell, David S. H. // American Family Physician;12/1/2001, Vol. 64 Issue 11, p1812
Editorial. Comments on the combination therapy for type 2 diabetes. Effectiveness of sulfonylurea as treatment for type 2 diabetes; Examination of the insulin therapy; Information on the combined insulin and oral therapy.
- Comparison of high fibre diets, basal insulin supplements, and flexible insulin treatment for non-insulin dependent (type II) diabetics poorly controlled with sulphonylureas. Scott, A.R.; Attenborough, Y.; Peacock, I.; Fletcher, E.; Jeffcoate, W.J.; Tattersall, R.B. // BMJ: British Medical Journal (International Edition);9/17/88, Vol. 297 Issue 6650, p707
Explores the efficacy of managements for non-insulin-dependent diabetes. Administration of high fiber diet, basal insulin supplements and a regimen of insulin for diabetics; Absence of changes in hemoglobin A[sub 1] concentration during high fiber diet; Improvement of control of diabetes by...
- Vildagliptin: A Review of its Use in the Management of Type 2 Diabetes Mellitus. Croxtall, Jamie D.; Keam, Susan J. // Drugs;2008, Vol. 68 Issue 16, p2387
Vildagliptin (GalvusÂ®) is an antihyperglycaemic agent that selectively inhibits the dipeptidyl peptidase-4 (DPP-4) enzyme. Such inhibition prevents the degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This results in...
- Phase I Study of FG-3019, an Anti-CTGF Monoclonal Antibody, in Type 1/2 Diabetes Mellitus with Microalbuminuria. Schwartz, Sherwyn; Williams, Mark E.; Arauz, Carlos; Bolton, Warren K.; Lee, Tyson; Coker, George; Sewell, K. Lea; Adler, Sharon G. // Diabetes;Jun2007 Supplement 1, Vol. 56, pA151
The article discusses a study on the use of FG-3019, an anti-CTGF monoclonal antibody, in type 1 and 2 diabetes mellitus with microalbuminuria. The patients showed well toleration of infusions without interruption for symptoms. The study was able to safely dose FG-3019 over 42 days in diabetics...
- Acarbose noninferior to metformin in type 2 diabetes. // Endocrine Today;Nov2013, Vol. 11 Issue 11, p9
The article discusses a research study published in an issue of the journal "The Lancet" which found that patients with type 2 diabetes treated with acarbose experienced similar improvements in HbAlc as those treated with metformin.
- On "Exercise assessment and prescription in patients with type 2 diabetes...". Gentzel, Joseph B.; Hansen, Dominique; Peeters, Stefaan; Schotte, Michel // Physical Therapy;Aug2013, Vol. 93 Issue 8, p1141
A letter to the editor is presented in response to the article "Exercise Assessment and Prescription in Patients With Type 2 Diabetes in the Private and Home Care Setting: Clinical Recommendations From AXXON (Belgian Physical Therapy Association)" by D. Hansen et al. in the May 2013 issue, along...
- A guide to combination therapy in type 2 diabetes. Codario, Ronald A. // Patient Care;Apr2003, Vol. 37 Issue 4, p16
Discusses the combination therapy for type 2 diabetes. Importance of tight glycemic control in type diabetes; Characteristics of oral antihyperglycemic agents; Information on recommended treatment strategies for type 2 diabetes.
- Recent advances in the treatment of type II diabetes mellitus. Baliga, Bantwal Suresh; Fonseca, Vivian A. // American Family Physician;2/15/1997, Vol. 55 Issue 3, p817
States that diabetes mellitus needs to be managed early in order to prevent the onset and progress of complications. What can be done to achieve and maintain good glycemic control; Limitations in addressing the fundamental abnormalities in the pathogenesis of type II diabetes mellitus;...